Use of Chromatin Changes as Biomarkers

Ryan A. Hlady, Keith D Robertson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The complexity of human disease and individual heterogeneity emphasizes the need for precision medicine. Biomarkers can be utilized for diagnosis, prognosis, and predicting treatment outcomes on a case-by-case basis. Recent advances in genome-wide techniques have led to a rapid expansion in our detection and understanding of epigenetic landscapes. These well-established epigenetic mechanisms, including DNA methylation, histone modifications, and miRNAs, are essential for normal development and are now intimately linked to disease phenotypes through their involvement in the regulation of gene transcription. Readout of these epigenetic marks provides three new avenues for discovery and implementation of biomarkers. Promising epigenetic targets are emerging as biomarkers of cancer, neurologic disorders, diabetes, and imprinting disorders. Understanding and interpreting the epigenome in human disease is critical for providing patients with individualized medical decisions and treatments. Panels of epigenetic biomarkers coupled with traditional markers are likely the future of noninvasive screens for diagnosis, prognosis, and informing treatment decisions.

Original languageEnglish (US)
Title of host publicationChromatin Signaling and Diseases
PublisherElsevier Inc.
Pages403-421
Number of pages19
ISBN (Electronic)9780128026090
ISBN (Print)9780128023891
DOIs
StatePublished - Aug 24 2016

Fingerprint

Biomarkers
Epigenomics
Chromatin
Genes
Transcription
Tumor Biomarkers
Medical problems
MicroRNAs
Histone Code
Histones
Medicine
Precision Medicine
DNA Methylation
Nervous System Diseases
Genome
Phenotype
Therapeutics

Keywords

  • Biomarker
  • Diagnostic
  • DNA methylation
  • Histone modification
  • MicroRNA
  • Precision medicine
  • Prognostic
  • Receiver operating characteristic
  • Therapeutic

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hlady, R. A., & Robertson, K. D. (2016). Use of Chromatin Changes as Biomarkers. In Chromatin Signaling and Diseases (pp. 403-421). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-802389-1.00022-8

Use of Chromatin Changes as Biomarkers. / Hlady, Ryan A.; Robertson, Keith D.

Chromatin Signaling and Diseases. Elsevier Inc., 2016. p. 403-421.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hlady, RA & Robertson, KD 2016, Use of Chromatin Changes as Biomarkers. in Chromatin Signaling and Diseases. Elsevier Inc., pp. 403-421. https://doi.org/10.1016/B978-0-12-802389-1.00022-8
Hlady RA, Robertson KD. Use of Chromatin Changes as Biomarkers. In Chromatin Signaling and Diseases. Elsevier Inc. 2016. p. 403-421 https://doi.org/10.1016/B978-0-12-802389-1.00022-8
Hlady, Ryan A. ; Robertson, Keith D. / Use of Chromatin Changes as Biomarkers. Chromatin Signaling and Diseases. Elsevier Inc., 2016. pp. 403-421
@inbook{4bf773778b054ed6877cf6c0ee6a8057,
title = "Use of Chromatin Changes as Biomarkers",
abstract = "The complexity of human disease and individual heterogeneity emphasizes the need for precision medicine. Biomarkers can be utilized for diagnosis, prognosis, and predicting treatment outcomes on a case-by-case basis. Recent advances in genome-wide techniques have led to a rapid expansion in our detection and understanding of epigenetic landscapes. These well-established epigenetic mechanisms, including DNA methylation, histone modifications, and miRNAs, are essential for normal development and are now intimately linked to disease phenotypes through their involvement in the regulation of gene transcription. Readout of these epigenetic marks provides three new avenues for discovery and implementation of biomarkers. Promising epigenetic targets are emerging as biomarkers of cancer, neurologic disorders, diabetes, and imprinting disorders. Understanding and interpreting the epigenome in human disease is critical for providing patients with individualized medical decisions and treatments. Panels of epigenetic biomarkers coupled with traditional markers are likely the future of noninvasive screens for diagnosis, prognosis, and informing treatment decisions.",
keywords = "Biomarker, Diagnostic, DNA methylation, Histone modification, MicroRNA, Precision medicine, Prognostic, Receiver operating characteristic, Therapeutic",
author = "Hlady, {Ryan A.} and Robertson, {Keith D}",
year = "2016",
month = "8",
day = "24",
doi = "10.1016/B978-0-12-802389-1.00022-8",
language = "English (US)",
isbn = "9780128023891",
pages = "403--421",
booktitle = "Chromatin Signaling and Diseases",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Use of Chromatin Changes as Biomarkers

AU - Hlady, Ryan A.

AU - Robertson, Keith D

PY - 2016/8/24

Y1 - 2016/8/24

N2 - The complexity of human disease and individual heterogeneity emphasizes the need for precision medicine. Biomarkers can be utilized for diagnosis, prognosis, and predicting treatment outcomes on a case-by-case basis. Recent advances in genome-wide techniques have led to a rapid expansion in our detection and understanding of epigenetic landscapes. These well-established epigenetic mechanisms, including DNA methylation, histone modifications, and miRNAs, are essential for normal development and are now intimately linked to disease phenotypes through their involvement in the regulation of gene transcription. Readout of these epigenetic marks provides three new avenues for discovery and implementation of biomarkers. Promising epigenetic targets are emerging as biomarkers of cancer, neurologic disorders, diabetes, and imprinting disorders. Understanding and interpreting the epigenome in human disease is critical for providing patients with individualized medical decisions and treatments. Panels of epigenetic biomarkers coupled with traditional markers are likely the future of noninvasive screens for diagnosis, prognosis, and informing treatment decisions.

AB - The complexity of human disease and individual heterogeneity emphasizes the need for precision medicine. Biomarkers can be utilized for diagnosis, prognosis, and predicting treatment outcomes on a case-by-case basis. Recent advances in genome-wide techniques have led to a rapid expansion in our detection and understanding of epigenetic landscapes. These well-established epigenetic mechanisms, including DNA methylation, histone modifications, and miRNAs, are essential for normal development and are now intimately linked to disease phenotypes through their involvement in the regulation of gene transcription. Readout of these epigenetic marks provides three new avenues for discovery and implementation of biomarkers. Promising epigenetic targets are emerging as biomarkers of cancer, neurologic disorders, diabetes, and imprinting disorders. Understanding and interpreting the epigenome in human disease is critical for providing patients with individualized medical decisions and treatments. Panels of epigenetic biomarkers coupled with traditional markers are likely the future of noninvasive screens for diagnosis, prognosis, and informing treatment decisions.

KW - Biomarker

KW - Diagnostic

KW - DNA methylation

KW - Histone modification

KW - MicroRNA

KW - Precision medicine

KW - Prognostic

KW - Receiver operating characteristic

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85018811955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018811955&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802389-1.00022-8

DO - 10.1016/B978-0-12-802389-1.00022-8

M3 - Chapter

SN - 9780128023891

SP - 403

EP - 421

BT - Chromatin Signaling and Diseases

PB - Elsevier Inc.

ER -